MAPT and tauopathy: A total of 60 clinical trials have been conducted to date with 24 different therapeutics targeting diverse proposed tauopathy mechanisms (Figure 3), an advance never before seen for tau and really “representing the dawn of a new age of drug development for Tau” [301].